<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859959</url>
  </required_header>
  <id_info>
    <org_study_id>PenAM</org_study_id>
    <nct_id>NCT04859959</nct_id>
  </id_info>
  <brief_title>Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses</brief_title>
  <official_title>Gallium-68 Labeled Pentixafor PET/CT in the Diagnosis and Characterization of Adrenal Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CXC chemokine receptor type 4 (CXCR4), which is a G protein-coupled receptor expressed on&#xD;
      the surface of the cell membrane, contributes to the development and progression of&#xD;
      malignancies and functional endocrine disorders. CXCR4 expression has been reported to be&#xD;
      upregulated in aldosterone-producing adenomas and cortisol-producing adenomas; however, its&#xD;
      expression is almost negligible in non-functioning adrenal adenomas. Besides, CXCR4 is also&#xD;
      hardly expressed by the tumor cells in paragangliomas. 68Ga-pentixafor, a CXCR4-specific PET&#xD;
      tracer, may therefore be effective for the evaluation of the functional lateralization of&#xD;
      adrenal lesion and identification of functional adrenocortical adenomas. In this pilot study,&#xD;
      we aimed to develop 68Ga-pentixafor PET/CT as a noninvasive test for the recognition of&#xD;
      functional adrenocortical lesions and to help guide the management of patients with&#xD;
      suspicious adrenal masses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identifying the functional distinctions between adrenal nodules remains challenging. It is&#xD;
      imperative to employ the least invasive approach for the functional evaluation of adrenal&#xD;
      masses (e.g., adrenal venous sampling) without compromising efficacy. The conventional&#xD;
      functional diagnosis protocol of adrenal masses is based on a combination of clinical&#xD;
      symptoms, the presence of adrenal hormonal disorders, and radiographic features. However, the&#xD;
      clinical manifestations of endocrine diseases are diverse, and a lack of uniformity in&#xD;
      diagnostic protocols and assay methods for determining hormonal activation in adrenal&#xD;
      disorders results in a significant variability in measurements. Besides, conventional imaging&#xD;
      provides information of the morphology of a lesion, but not its functional status. Thus, an&#xD;
      effective and non-invasive workup is needed for the characterization of adrenal masses and&#xD;
      their therapeutic management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The diagnosis efficiency</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>The diagnosis efficiency of functional lateralization and identification of functional adrenocortical adenomas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard uptake value (SUV)</measure>
    <time_frame>From right after tracer injection to 2-hours post-injection</time_frame>
    <description>Determination of SUV for detected lesions and normal liver and adrenal tissue of 68Ga-Pentixafor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Adrenal Mass</condition>
  <arm_group>
    <arm_group_label>68Ga-Pentixafor PET/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Inject 68Ga-Pentixafor and perform PET/CT scan 1h later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gallium-68 Pentixafor PET/CT</intervention_name>
    <description>Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.</description>
    <arm_group_label>68Ga-Pentixafor PET/CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patients with adrenal diseases.&#xD;
&#xD;
          -  A diagnostic computed tomography (CT) or magnetic resonance imaging (MRI) of the&#xD;
             adrenal region within the previous 6 months prior to dosing day is available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Prior or planned administration of a radiopharmaceutical within 8 half-lives of the&#xD;
             radionuclide used on such radiopharmaceutical including at any time during the current&#xD;
             study.&#xD;
&#xD;
          -  Any mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study, and/or evidence of an uncooperative attitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Huo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Ding, MD</last_name>
    <phone>+86 17810259215</phone>
    <email>707462902@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Huo, MD</last_name>
    <phone>+86 13910801986</phone>
    <email>huoli@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Peking</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuyang Zhang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

